Literature DB >> 1493354

Prevention of osteoporosis. Current recommendations.

M C Ellerington1, J C Stevenson.   

Abstract

Osteoporosis and its treatment have attracted much attention in recent years, especially since the widespread recognition of its association with the menopause. The resulting fractures are a cause of considerable morbidity and mortality in the elderly, and current costs of treating these patients has been estimated to be in excess of pounds 500 million per annum in the UK. As the causes of osteoporosis are now recognised the condition may be largely preventable, especially in women, and significant savings in health expenditure could be made if preventive methods are applied to those most at risk. The most well researched preventive treatment for osteoporosis is hormone replacement therapy (HRT) which offers additional benefits to those who choose it. Alternative methods currently under investigation for those who cannot or will not use HRT include those agents which inhibit the resorption of bone and those that stimulate the production of new bone. Treatment of established disease, i.e. attempts at increasing bone density in those with significant loss, is more difficult and methods so far investigated are not without risks and adverse effects. Furthermore, whether an increase in bone mineral density results in a reduced rate of fracture incidence has yet to be confirmed.

Entities:  

Mesh:

Year:  1992        PMID: 1493354     DOI: 10.2165/00002512-199202060-00006

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  60 in total

1.  Nasal calcitonin for treatment of established osteoporosis.

Authors:  K Overgaard; B J Riis; C Christiansen; J Pødenphant; J S Johansen
Journal:  Clin Endocrinol (Oxf)       Date:  1989-04       Impact factor: 3.478

2.  Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.

Authors:  B L Riggs; S F Hodgson; W M O'Fallon; E Y Chao; H W Wahner; J M Muhs; S L Cedel; L J Melton
Journal:  N Engl J Med       Date:  1990-03-22       Impact factor: 91.245

3.  The minimum effective dose of estrogen for prevention of postmenopausal bone loss.

Authors:  R Lindsay; D M Hart; D M Clark
Journal:  Obstet Gynecol       Date:  1984-06       Impact factor: 7.661

4.  Comparison of pharmacodynamic properties of various estrogen formulations.

Authors:  C A Mashchak; R A Lobo; R Dozono-Takano; P Eggena; R M Nakamura; P F Brenner; D R Mishell
Journal:  Am J Obstet Gynecol       Date:  1982-11-01       Impact factor: 8.661

5.  Estrogen therapy arrests bone loss in elderly women.

Authors:  M E Quigley; P L Martin; A M Burnier; P Brooks
Journal:  Am J Obstet Gynecol       Date:  1987-06       Impact factor: 8.661

6.  Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins.

Authors:  D Crook; M P Cust; K F Gangar; M Worthington; T C Hillard; J C Stevenson; M I Whitehead; V Wynn
Journal:  Am J Obstet Gynecol       Date:  1992-03       Impact factor: 8.661

7.  Oral contraceptives. Renin, aldosterone, and high blood pressure.

Authors:  J H Laragh; J E Sealey; J G Ledingham; M A Newton
Journal:  JAMA       Date:  1967-09-18       Impact factor: 56.272

8.  Calcitonin and the calcium-regulating hormones in postmenopausal women: effect of oestrogens.

Authors:  J C Stevenson; G Abeyasekera; C J Hillyard; K G Phang; I MacIntyre; S Campbell; P T Townsend; O Young; M I Whitehead
Journal:  Lancet       Date:  1981-03-28       Impact factor: 79.321

9.  Prostaglandin production by calvariae from sham operated and oophorectomized rats: effect of 17 beta-estradiol in vivo.

Authors:  J H Feyen; L G Raisz
Journal:  Endocrinology       Date:  1987-08       Impact factor: 4.736

Review 10.  Diphosphonates: history and mechanisms of action.

Authors:  H Fleisch
Journal:  Metab Bone Dis Relat Res       Date:  1981
View more
  4 in total

Review 1.  Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.

Authors:  G L Plosker; D McTavish
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

Review 2.  Can thiazide diuretics be recommended routinely to reduce hip fracture risk?

Authors:  P B Thapa; W A Ray
Journal:  Drugs Aging       Date:  1993 Mar-Apr       Impact factor: 3.923

Review 3.  Prevention and treatment of postmenopausal osteoporosis.

Authors:  R B Hallworth
Journal:  Pharm World Sci       Date:  1998-10

Review 4.  Musculoskeletal disease in the aged. Diagnosis and management.

Authors:  R F Afable; W H Ettinger
Journal:  Drugs Aging       Date:  1993 Jan-Feb       Impact factor: 3.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.